TRDA.O (TRDA.O) News
Follow TRDA.O (TRDA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Entrada Therapeutics advances ENTR — 601 — 44 Phase 1/2 DMD trial to 18 mg/kg Cohort 3 after DMC review
Entrada Therapeutics moved its ELEVATE-44-201 study into Cohort 3 at the top 18 mg/kg dose following a safety committee review. The committee reviewed available safety and drug-behavior data from eight Cohort 2 participa
NEWS | Oct 14, 2026, 11:05 AM UTC
L
Entrada reports Phase 1/2 ELEVATE — 45 — 201 Cohort 1 data showing ENTR — 601 — 45 meets safety, tolerability goals in Duchenne muscular dystrophy trial
Entrada Therapeutics released positive topline results already reported from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study in Duchenne muscular dystrophy. The initial-dose cohort met the main goal on safety and tolerabi
NEWS | Oct 14, 2026, 11:05 AM UTC